|
1
|
National Cancer Institute: Cancer
Statistics, . https://www.cancer.gov/about-cancer/understanding/statisticsMay
18–2017
|
|
2
|
McLemore MR, Miaskowski C, Aouizerat BE,
Chen LM and Dodd MJ: Epidemiologic and genetic factors associated
with ovarian cancer. Cancer Nurs. 32:281–290. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vajpeyi R: WHO Classification of Tumours:
Pathology and Genetics of Tumours of the Breast and Female Genital
Organs. J Clin Pathol. 58:671–672. 2005.PubMed/NCBI
|
|
4
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim A, Ueda Y, Naka T and Enomoto T:
Therapeutic strategies in epithelial ovarian cancer. J Exp Clin
Cancer Res. 31:142012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Argento M, Hoffman P and Gauchez AS:
Ovarian cancer detection and treatment: Current situation and
future prospects. Anticancer Res. 28:3135–3138. 2008.PubMed/NCBI
|
|
7
|
Morgado M, Sutton MN, Simmons M, Warren
CR, Lu Z, Constantinou PE, Liu J, Francis LL, Conlan RS, Bast RC Jr
and Carson DD: Tumor necrosis factor-α and interferon-γ stimulate
MUC16 (CA125) expression in breast, endometrial and ovarian cancers
through NFκB. Oncotarget. 7:14871–14884. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Norum LF, Erikstein B and Nustad K:
Elevated CA125 in breast cancer--A sign of advanced disease. Tumour
Biol. 22:223–228. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng X, Gou HF, Liu JY, Luo DY and Qiu M:
Clinical significance of serum CA125 in diffuse malignant
mesothelioma. SpringerPlus. 5:3682016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Namikawa T, Kawanishi Y, Fujisawa K,
Munekage E, Iwabu J, Munekage M, Maeda H, Kitagawa H, Kobayashi M
and Hanazaki K: Serum carbohydrate antigen 125 is a signifcant
prognostic marker in patients with unresectable advanced or
recurrent gastric cancer. Surg Today. 48:388–394. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Memar B, Aledavood A, Shahidsales S, Ahadi
M, Farzadnia M, Raziee H, Noori S, Tayebi-Meybodi N, Amouian S and
Mohtashami S: The Prognostic Role of Tumor Marker CA-125 in B-Cell
non-Hodgkin's Lymphoma. Iran J Cancer Prev. 8:42–46.
2015.PubMed/NCBI
|
|
12
|
Baalbergen A, Janssen JW and van der
Weiden RM: CA-125 levels are related to the likelihood of pregnancy
after in vitro fertilization and embryo transfer. Am J Reprod
Immunol. 43:21–24. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bon GG, Kenemans P, Dekker JJ, Hompes PG,
Verstraeten RA, van Kamp GJ and Schoemaker J: Fluctuations in CA
125 and CA 15-3 serum concentrations during spontaneous ovulatory
cycles. Hum Reprod. 14:566–570. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Das S and Batra K: Understanding the
unique attributes of MUC16 (CA125): Potential implications in
targeted therapy. Cancer Res. 75:4669–4674. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hoogstad-van Evert JS, Maas RJ, Van der
Meer J, Cany J, Van der Steen S, Jansen JH, Miller JS, Bekkers R,
Hobo W, Massuger L and Dolstra H: Peritoneal NK cells are
responsive to IL-15 and percentages are correlated with outcome in
advanced ovarian cancer patients. Oncotarget. 9:34810–34820.
2018.PubMed/NCBI
|
|
16
|
Su Y, Tatzel K, Wang X, Belt B, Binder P,
Kuroki L, Powell MA, Mutch DG, Hawkins WG and Spitzer D:
Mesothelin's minimal MUC16 binding moiety converts TR3 into a
potent cancer therapeutic via hierarchical binding events at the
plasma membrane. Oncotarget. 7:31534–31549. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He X, Wang L, Riedel H, Wang K, Yong Y,
Dinu CZ and Rojanasakul Y: Mesothelin promotes
epithelial-to-mesenchymal transition and tumorigenicity of human
lung cancer and mesothelioma cells. Mol Cancer. 16:632017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chanvorachote P, Luanpitpong S, Chunhacha
P, Promden W and Sriuranpong V: Expression of CA125 and cisplatin
susceptibility of pleural effusion-derived human lung cancer cells
from a Thai patient. Oncol Lett. 4:252–256. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shukla SK, Gunda V, Abrego J, Haridas D,
Mishra A, Souchek J, Chaika NV, Yu F, Sasson AR, Lazenby AJ, et al:
MUC16-mediated activation of mTOR and c-MYC reprograms pancreatic
cancer metabolism. Oncotarget. 6:19118–19131. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Victorelli S and Passos J: Telomeres and
cell senescence - size matters not. EBioMedicine. 21:14–20. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shay JW and Wright WE: Senescence and
immortalization: Role of telomeres and telomerase. Carcinogenesis.
26:867–874. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Meng E, Taylor B, Ray A, Shevde LA and
Rocconi RP: Targeted inhibition of telomerase activity combined
with chemotherapy demonstrates synergy in eliminating ovarian
cancer spheroid-forming cells. Gynecol Oncol. 124:598–605. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Greider CW: Regulating telomere length
from the inside out: The replication fork model. Genes Dev.
30:1483–1491. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koh CM, Khattar E, Leow SC, Liu CY, Muller
J, Ang WX, Li Y, Franzoso G, Li S, Guccione E and Tergaonkar V:
Telomerase regulates MYC-driven oncogenesis independent of its
reverse transcriptase activity. J Clin Invest. 125:2109–2122. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu J, Blenis J and Yuan J: Activation of
PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by
phosphorylating and promoting the degradation of Mad1. Proc Natl
Acad Sci U S A. 105:6584–6589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang S, Li Y, Wu Y, Shi K, Bing L and Hao
J: Wnt/β-catenin signaling pathway upregulates c-Myc expression to
promote cell proliferation of p19 teratocarcinoma cells. Anat Rec
(Hoboken). 295:2104–2113. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aunoble B, Sanches R, Didier E and Bignon
Y: Major oncogenes and tumor suppressor genes involved in
epithelial ovarian cancer (Review). Int J Oncol. 16:567–576.
2000.PubMed/NCBI
|
|
28
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ma Y, Wang W, Idowu MO, Oh U, Wang XY,
Temkin SM and Fang X: Ovarian cancer relies on glucose transporter
1 to fuel glycolysis and growth: Anti-tumor activity of BAY-876.
Cancers (Basel). 11:E332018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fang S and Fang X: Advances in glucose
metabolism research in colorectal cancer. Biomed Rep. 5:289–295.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schroll MM, LaBonia GJ, Ludwig KR and
Hummon AB: Glucose restriction combined with autophagy inhibition
and chemotherapy in HCT 116 spheroids decreases cell clonogenicity
and viability regulated by tumor suppressor genes. J Proteome Res.
16:3009–3018. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wardi L, Alaaeddine N, Raad I, Sarkis R,
Serhal R, Khalil C and Hilal G: Glucose restriction decreases
telomerase activity and enhances its inhibitor response on breast
cancer cells: Possible extra-telomerase role of BIBR 1532. Cancer
Cell Int. 14:602014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian caner: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gamarra-Luques CD, Hapon MB, Goyeneche AA
and Telleria CM: Resistance to cisplatin and paclitaxel does not
affect the sensitivity of human ovarian cancer cells to
antiprogestin-induced cytotoxicity. J Ovarian Res. 7:452014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cawthon R: Telomere measurement by
quantitative PCR. Nucleic Acids Res. 30:e472002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rao X, Huang X, Zhou Z and Lin X: An
improvement of the 2(-delta delta CT) method for quantitative
real-time polymerase chain reaction data analysis. Biostat
Bioinforma Biomath. 3:71–85. 2013.PubMed/NCBI
|
|
39
|
Zhou M, Zhao Y, Ding Y, Liu H, Liu Z,
Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, et al: Warbug
effect in chemosensitivity: Targeting lactate dehydrogenase-A
re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer.
9:332010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Glasgow C, Pacheco-Rodriguez G, Steagall
WK, Haughey ME, Julien-Williams PA, Stylianou MP, Gochuico BR and
Moss J: CA-125 in disease progression and treatment of
lymphangioleiomyomatosis. Chest. 153:339–348. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu
W, Liu J, Xiang J, Liang D, Hu Q, et al: Oncogenic KRAS targets
MUC16/CA125 in pancreatic ductal adenocarcinoma. Mol Cancer Res.
15:201–212. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Muallem MZ, Braicu I, Nassir M, Richter R,
Sehouli J and Arsenic R: ERCC1 expression as a predictor of
resistance to platinum-based chemotherapy in primary ovarian
cancer. Anticancer Res. 34:393–399. 2014.PubMed/NCBI
|
|
43
|
Meads MB, Gatenby RA and Dalton WS:
Environment-mediated drug resistance: A major contributor to
minimal residual disease. Nat Rev Cancer. 9:665–674. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bapat SA, Mali AM, Koppikar CB and Kurrey
NK: Stem and progenitor-like cells contribute to the aggressive
behavior of human epithelial ovarian cancer. Cancer Res.
65:3025–3059. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kigawa J: New strategy for overcoming
resistance to chemotherapy of ovarian cancer. Yonago Acta Med.
56:43–50. 2013.PubMed/NCBI
|
|
46
|
Zhao Y, Liu H, Liu Z, Ding Y, LeDoux SP,
Wilson GL, Voellmy R, Lin Y, Lin W, Nahta R, et al: Overcoming
trastuzumab resistance in breast cancer by targeting dysregulated
glucose metabolism. Cancer Res. 71:4585–4597. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Guo XL, Ma NN, Zhou FG, Zhang L, Bu XX,
Sun K, Song JR, Li R, Zhang BH, Wu MC and Wei LX: Up-regulation of
hTERT expression by low-dose cisplatin contributes to chemotherapy
resistance in human hepatocellular cancer cells. Oncol Rep.
22:549–556. 2009.PubMed/NCBI
|
|
48
|
Boivin M, Lane D, Piché A and Rancourt C:
CA125 (MUC16) tumor antigen selectively modulates the sensitivity
of ovarian cancer cells to genotoxic drug-induced apoptosis.
Gynecol Oncol. 115:407–413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bonneau C, Rouzier R, Geyl C, Cortez A,
Castela M, Lis R, Daraï E and Touboul C: Predictive markers of
chemoresistance in advanced stages epithelial ovarian carcinoma.
Gynecol Oncol. 136:112–120. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang Z, Yu L, Dai G, Xia K, Liu G, Song
Q, Tao C, Gao T and Guo W: Telomerase reverse transcriptase
promotes chemoresistance by suppressing cisplatin-dependent
apoptosis in osteosarcoma cells. Sci Rep. 7:70702017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sotillo-Piñeiro E, Sierrasesúmaga L and
Patiño-García A: Telomerase activity and telomere length in primary
and metastatic tumors from pediatric bone cancer patients. Pediatr
Res. 55:231–235. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tian C, Markman M, Zaino R, Ozols RF,
McGuire WP, Muggia FM, Rose PG, Spriggs D and Armstrong DK: CA-125
change following chemotherapy in prediction of treatment outcome
among advanced mucinous and clear cell epithelial ovarian cancers:
A gynecologic oncology group study. Cancer. 115:1395–1403. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li Y and Tergaonkar V: Noncanonical
functions of telomerase: Implications in telomerase-targeted cancer
therapies. Cancer Res. 74:1639–1644. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sapi E, Okpokwasili NI and Rutherford T:
Detection of telomerase-positive circulating epithelial cells in
ovarian cancer patients. Cancer Detect Prev. 26:158–167. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Maraei AA, Hatta AZ, Shiran MS and Tan GC:
Human telomerase reverse transcriptase expression in ovarian
tumors. Indian J Pathol Microbiol. 55:187–191. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bharadwaj U, Marin-Muller C, Li M, Chen C
and Yao Q: Mesothelin confers pancreatic cancer cell resistance to
TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and
IL-6/Mcl-1 overexpression. Mol Cancer. 10:1062011. View Article : Google Scholar : PubMed/NCBI
|
